Suspending agent containing abamectin and cyflumetofen as well as preparation method and application of suspending agent

Abstract

The invention belongs to the technical field of pesticide preparations, and discloses a suspending agent containing abamectin and cyflumetofen as well as a preparation method and application of the suspending agent, the suspending agent comprises the following components in percentage by mass: 25%-32% of active carrier particles, 0.4%-3% of a thickening agent, 0.1%-0.8% of a preservative and 2%-8% of an anti-freezing agent, each active carrier particle comprises an inner core and a shell layer, the inner core comprises mesoporous activated carbon, nano-silazite, abamectin, cyflumetofen and azobenzene, the nano-silazite is dispersed in pores of the mesoporous activated carbon, the abamectin, the cyflumetofen and the azobenzene are all adsorbed on the nano-silazite, and the shell layer is amino silicon oil. According to the invention, efficient slow release, long-acting stability and environmental friendliness of pesticides can be realized, the problems of easy degradation of active components, low utilization rate, unstable storage and the like of a traditional suspending agent are solved, and the suspending agent has agricultural application value.

Description

Technical Field

[0001] The invention belongs to the technical field of pesticide preparations, and particularly relates to a suspension concentrate containing abamectin and cyflumetofen, and a preparation method and application thereof. Background Art

[0002] Although pesticide suspension concentrates are widely used in agricultural pest control due to their advantages such as good environmental protection and long-lasting efficacy, when faced with fat-soluble active ingredients such as abamectin and cyflumetofen, traditional suspension concentrates rely on simple dispersion systems, and there is a problem of mismatch between the release rate of active ingredients and the occurrence cycle of pests and diseases, which manifests as excessive release in the early stage and insufficient efficacy in the later stage, leading to pesticide waste and environmental pollution. At the same time, as abamectin and cyflumetofen are fat-soluble ingredients, conventional dispersants are difficult to achieve stable dispersion, and particle agglomeration and sedimentation are prone to occur. In addition, the increase in temperature during processing will cause the active ingredients to decompose, seriously restricting industrial production. Summary of the Invention

[0003] The present invention aims to improve at least one technical problem in the background technology.

[0004] The first aspect of the present invention provides a suspension concentrate containing abamectin and cyflumetofen, which comprises, by mass percentage, 25%-32% of active carrier particles, 0.4%-3% of thickener, 0.1%-0.8% of preservative, and 2%-8% of antifreeze; The active carrier particles include an inner core and a shell layer, wherein the inner core includes mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene, the nano-attapulgite is dispersed in the pores of the mesoporous activated carbon, and abamectin, cyflumetofen and azobenzene are all adsorbed on the nano-attapulgite, and the shell layer is aminosilicone oil; the mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene and aminosilicone oil is (0.6-1.5):(0.6-1.8):(0.4-1):(0.6-1.2):(0.1-2):(0.05-0.6).

[0005] The active ingredients, abamectin and cyflumetofen, in the suspension concentrate of this invention are carried on specially structured active carrier particles. The mesoporous activated carbon within the core of the active carrier particles provides a high specific surface area and a rich pore structure. Nano-attapulgite is dispersed within the pores of the mesoporous activated carbon, forming a stable network through hydrogen bonding (-OH groups of the mesoporous activated carbon and -OH2 groups of the nano-attapulgite). Abamectin and cyflumetofen adsorb on the nano-attapulgite, slowing the release of the active ingredients. The aminosilicone oil shell encapsulates the core, forming a hydrophobic protective film that reduces the dissolution loss of abamectin and cyflumetofen in water and prolongs the storage stability of the suspension concentrate. The abundant pores within the aminosilicone oil shell allow for the gradual release of abamectin and cyflumetofen molecules through diffusion. Furthermore, the -NH2 groups on the aminosilicone oil are protonated in water and become positively charged. This electrostatic repulsion prevents agglomeration between the active carrier particles, ensuring their uniform dispersion within the suspension concentrate. On this basis, the azobenzene in the core can undergo a trans-cis conformational transition under ultraviolet-visible light irradiation and expand in volume, thereby squeezing the pores of the aminosilicone oil shell to temporarily expand it, while disturbing the abamectin and cyflumetofen adsorbed on the nano-magnesia clay, accelerating the release of abamectin and cyflumetofen from the active carrier particles, and realizing light-responsive sustained release.

[0006] Other additives are also added to the suspension concentrate of the present invention, among which a thickener is used to increase the viscosity of the suspension concentrate, slow down the particle settling rate, and maintain the uniformity of the suspension concentrate system; a preservative is used to inhibit the growth of microorganisms and prevent the suspension concentrate from deteriorating; and an antifreeze is used to lower the freezing point of the system to prevent water from freezing and destroying the particle structure in a low-temperature environment, thereby ensuring product stability.

[0007] Preferably, the mass ratio of mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene, and aminosilicone oil is (0.8-1.2):(0.75-1.5):(0.5-0.75):(0.8-1):(0.2-1.5):(0.1-0.45). When the above mass ratio is adopted, the implementation effect is better.

[0008] Furthermore, the median particle size D50 of the active carrier particles is 2 μm-15 μm, and the maximum particle size D90 of the active carrier particles is 10 μm-30 μm.

[0009] Furthermore, the mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: soaking the mesoporous activated carbon in a phosphoric acid solution for 5h-12h, and heating it at 400℃-500℃ for 1h-3h after drying; the mass concentration of the phosphoric acid solution is 30%-50%.

[0010] The present invention performs an activation treatment on the mesoporous activated carbon. After the mesoporous activated carbon is activated with a phosphoric acid solution, more -OH groups are formed on the surface of the mesoporous activated carbon, which is more conducive to the dispersion of nano-attapulgite in the pores of the mesoporous activated carbon. In addition, the phosphoric acid solution activation is relatively mild and does not damage the pore structure of the mesoporous activated carbon.

[0011] Furthermore, the thickener includes at least one of gum arabic, xanthan gum, carboxymethyl cellulose, bentonite and magnesium aluminum silicate.

[0012] The present invention prefers the above-mentioned thickeners, among which gum arabic can enhance the viscosity of the suspension system by forming a three-dimensional network structure, establish a physical barrier between active carrier particles, and significantly reduce the particle sedimentation rate; xanthan gum has unique pseudoplastic rheological properties, with high viscosity under low shear, preventing particle sedimentation, and a sharp drop in viscosity under high shear, facilitating the spray operation of the suspension; carboxymethyl cellulose stabilizes the dispersion of active carrier particles through the dual mechanisms of electrostatic repulsion and steric hindrance; the lamellar structure of bentonite can expand in water to form a gel layer, preventing the agglomeration of active carrier particles; and magnesium aluminum silicate rapidly expands in water to form a three-dimensional network colloidal structure, thereby significantly increasing the viscosity of the system.

[0013] Furthermore, the preservative includes at least one of sorbic acid, sodium sorbate, benzoic acid, sodium benzoate and benzisothiazolinone.

[0014] The present invention prefers the above-mentioned preservatives, among which sorbic acid and sodium sorbate exert an antibacterial effect by inhibiting the activity of the microbial enzyme system. The conjugated double bonds in their molecular structure can weakly interact with the silicon-oxygen bonds in the aminosilicone oil film layer, forming an antibacterial barrier on the surface of the active carrier particles; benzoic acid and sodium benzoate penetrate the microbial cell membrane through lipophilicity, interfere with its permeability, and inhibit the activity of the intracellular respiratory enzyme system, thereby hindering the metabolism and growth of the microorganisms; benzisothiazolinone exerts a bactericidal effect by inhibiting the thiol groups in the microbial cells.

[0015] Furthermore, the antifreeze agent includes at least one of ethylene glycol, propylene glycol, glycerol and urea.

[0016] The present invention prefers the above-mentioned antifreeze agents, among which ethylene glycol, propylene glycol and glycerol have strong freezing point depression ability and hinder ice crystal growth by forming a hydrogen bond network with water; urea has a significant freezing point depression effect and has foliar nutrition function and can also be absorbed and utilized by plants.

[0017] The second aspect of the present invention provides a method for preparing the above-mentioned suspension concentrate containing abamectin and cyflumetofen, comprising the following steps: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, a thickener, a preservative and an antifreeze agent are added and mixed for a third time to obtain a suspension containing abamectin and cyflumetofen.

[0018] The first mixing is carried out under ultrasonic conditions, the ultrasonic power is 300W-500W, the first mixing time is 30min-2h; the temperature of the spray drying granulation is 80℃-110℃.

[0019] The third aspect of the present invention provides the use of the above-mentioned suspension concentrate containing abamectin and cyflumetofen in pesticides.

[0020] The beneficial effects of the present invention are as follows: the present invention can achieve efficient sustained release of pesticides, long-term stability and environmental friendliness, solves the problems of easy degradation of active ingredients, low utilization rate and unstable storage in traditional suspension concentrates, and has agricultural application value. DETAILED DESCRIPTION

[0021] Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiments are only used to illustrate the present invention and are not used in limiting the scope of the present invention.In addition, should be understood that after reading the content of the present invention record, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall equally within the scope limited by the application's appended claims.

[0022] Example 1 A suspension concentrate containing abamectin and cyflumetofen, comprising, by mass percentage, 25% active carrier particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance being water; The active carrier particles include a core and a shell, the core including mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene, the nano-attapulgite is dispersed in the pores of the mesoporous activated carbon, and abamectin, cyflumetofen and azobenzene are adsorbed on the nano-attapulgite. The shell is amino silicone oil; the mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene and amino silicone oil is 1:1:0.6:0.8:1:0.3; The median particle size D50 of the active carrier particles is 8.3 μm, and the maximum particle size D90 of the active carrier particles is 17.5 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0023] The preparation method of the suspension concentrate containing abamectin and cyflumetofen in Example 1 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension containing abamectin and cyflumetofen.

[0024] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0025] Example 2 A suspension concentrate containing abamectin and cyflumetofen, comprising, by mass percentage, 30% active carrier particles, 2.8% carboxymethyl cellulose (thickener), 0.7% benzisothiazolinone (preservative), 6% urea (antifreeze), and the balance being water; The active carrier particles include a core and a shell, the core including mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene, the nano-attapulgite is dispersed in the pores of the mesoporous activated carbon, and abamectin, cyflumetofen and azobenzene are adsorbed on the nano-attapulgite. The shell is amino silicone oil; the mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene and amino silicone oil is 1:0.75:0.75:0.9:1.3:0.4; The median particle size D50 of the active carrier particles is 10.2 μm, and the maximum particle size D90 of the active carrier particles is 21.7 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0026] The preparation method of the suspension concentrate containing abamectin and cyflumetofen in Example 2 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension containing abamectin and cyflumetofen.

[0027] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 350W, and the first mixing time was 3 hours; the temperature for spray drying granulation was 90°C.

[0028] Example 3 A suspension concentrate containing abamectin and cyflumetofen, comprising, by mass percentage, 28% active carrier particles, 2.5% gum arabic (thickener), 0.8% sodium sorbate (preservative), 5% propylene glycol (antifreeze), and the balance water; The active carrier particles include a core and a shell. The core includes mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen, and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. Abamectin, cyflumetofen, and azobenzene are all adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene, and amino silicone oil is 0.7:1.2:1:1:0.8:0.6. The median particle size D50 of the active carrier particles is 9.7 μm, and the maximum particle size D90 of the active carrier particles is 22.1 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0029] The preparation method of the suspension concentrate containing abamectin and cyflumetofen in Example 3 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, gum arabic, sodium sorbate and propylene glycol are added and mixed for a third time to obtain a suspension containing avermectin and cyflumetofen.

[0030] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 400W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0031] Example 4 A suspension concentrate containing abamectin and cyflumetofen, comprising, by mass percentage, 31% active carrier particles, 3% xanthan gum (thickener), 0.7% sodium benzoate (preservative), 8% ethylene glycol (antifreeze), and the balance water; The active carrier particles include a core and a shell. The core includes mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen, and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. Abamectin, cyflumetofen, and azobenzene are all adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene, and amino silicone oil is 1.4:0.9:0.7:0.6:1.3:0.5. The median particle size D50 of the active carrier particles is 13.3 μm, and the maximum particle size D90 of the active carrier particles is 27.1 μm.

[0032] The preparation method of the suspension concentrate containing abamectin and cyflumetofen in Example 4 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, xanthan gum, sodium benzoate and ethylene glycol are added and mixed for a third time to obtain a suspension containing avermectin and cyflumetofen.

[0033] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 500W, and the first mixing time was 1 hour; the temperature of the spray drying granulation was 80°C.

[0034] Comparative Example 1 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon, and abamectin, cyflumetofen and azobenzene are adsorbed on the nano-attapulgite. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen and azobenzene is 1:1:0.6:0.8:1. The median particle size D50 of the active particles is 9.6 μm, and the maximum particle size D90 of the active particles is 18.4 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0035] The preparation method of the suspension concentrate of Comparative Example 1 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are dispersed in water, and then carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for the third time to obtain a suspension.

[0036] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0037] Comparative Example 2 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include a core and a shell. The core includes mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. Abamectin, cyflumetofen and azobenzene are all adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene and amino silicone oil is 1:1:0.6:0.8:1:1.5. The median particle size D50 of the active particles is 10.4 μm, and the maximum particle size D90 of the active particles is 20.6 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0038] The preparation method of the suspending agent of Comparative Example 2 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension.

[0039] Comparative Example 3 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include a core and a shell. The core includes mesoporous activated carbon, nano-attapulgite, abamectin, and cyflumetofen. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. Both abamectin and cyflumetofen are adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, and amino silicone oil is 1:1:0.6:0.8:0.3. The median particle size D50 of the active particles is 8.7 μm, and the maximum particle size D90 of the active particles is 18.4 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0040] The preparation method of the suspension concentrate of Comparative Example 3 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin and cyflumetofen to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension.

[0041] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0042] Comparative Example 4 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include a core and a shell. The core includes mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. Abamectin, cyflumetofen and azobenzene are all adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of the mesoporous activated carbon, attapulgite, abamectin, cyflumetofen, azobenzene and amino silicone oil is 1:1:0.6:0.8:3:0.3. The median particle size D50 of the active particles is 9.0 μm, and the maximum particle size D90 of the active particles is 18.6 μm; The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: immersing the mesoporous activated carbon in a phosphoric acid solution for 6 hours, drying it, and heating it at 450° C. for 2 hours; the mass concentration of the phosphoric acid solution is 50%.

[0043] The preparation method of the suspension concentrate of Comparative Example 4 is as follows: The mesoporous activated carbon and nano-attapulgite are mixed and dispersed in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension.

[0044] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0045] Comparative Example 5 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include a core and a shell. The core includes abamectin, cyflumetofen and azobenzene, and the shell is aminosilicone oil. The mass ratio of abamectin, cyflumetofen, azobenzene and aminosilicone oil is 0.6:0.8:1:0.3. The median particle size D50 of the active particles was 6.9 μm, and the maximum particle size D90 of the active particles was 11.7 μm.

[0046] The preparation method of the suspension concentrate of Comparative Example 5 is as follows: Abamectin, cyflumetofen and azobenzene are first mixed and spray-dried to obtain first granules; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension.

[0047] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 30 minutes; the temperature for spray drying granulation was 100°C.

[0048] Comparative Example 6 A suspension concentrate comprising, by mass percentage, 25% active particles, 1.2% carboxymethyl cellulose (thickener), 0.4% benzisothiazolinone (preservative), 4% urea (antifreeze), and the balance water; The active particles include a core and a shell. The core includes mesoporous silica, nano-attapulgite, abamectin, cyflumetofen, and azobenzene. The nano-attapulgite is dispersed in the pores of the mesoporous activated carbon. The abamectin, cyflumetofen, and azobenzene are all adsorbed on the nano-attapulgite. The shell is amino silicone oil. The mass ratio of mesoporous silica, attapulgite, abamectin, cyflumetofen, azobenzene, and amino silicone oil is 1:1:0.6:0.8:1:0.3. The median particle size D50 of the active particles was 8.3 μm, and the maximum particle size D90 of the active particles was 17.5 μm.

[0049] The preparation method of the suspension concentrate of Comparative Example 6 is as follows: Mixing mesoporous silica and nano-attapulgite and dispersing them in water to obtain a dispersion; Adding abamectin, cyflumetofen and azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with amino silicone oil for a second time, and then dispersed in water. Finally, carboxymethyl cellulose, benzisothiazolinone and urea are added and mixed for a third time to obtain a suspension.

[0050] The first mixing was carried out under ultrasonic conditions, the ultrasonic power was 300W, and the first mixing time was 2h; the temperature for spray drying granulation was 100°C.

[0051] Physical and chemical performance test: The products prepared in Examples 1-4 and Comparative Examples 1-6 were subjected to physical and chemical property tests. The pH was tested according to CIPAC MT 75, with an index control range of 6.00-9.00; the foam persistence was tested according to CIPAC MT 47.2, with an index control range of ≤25 mL (after 1 minute); the pourability was tested according to CIPAC MT 148.1, with an index control range of ≤5% residue after pouring and ≤0.5% residue after washing; the hot storage stability was tested according to CIPAC MT 46.3, with an index control range of "pass"; and the low-temperature stability was tested according to CIPAC MT 39.3, with an index control range of "pass". The results of the physical and chemical property tests are shown in Tables 1 and 2.

[0052] Table 1 Physical and chemical properties test results of Examples 1-4 and Comparative Example 1 Table 2 Physical and chemical properties test results of comparative examples 2-6 Efficacy test: The products prepared in Example 1, Example 3, and Comparative Examples 1-6 were subjected to efficacy tests. The test crop was cabbage, and the main targets of field control were 1-2 instar larvae. The product spray rate was 110 mL per square meter. The number of field pests was investigated on the 1st, 3rd, 7th, 14th, 28th, and 60th day after application, and the control effect was calculated. Each group of tests was repeated 3 times and the average value was taken. The control effect is shown in Table 3.

[0053] Table 3 Results of efficacy tests on the products obtained in Example 1, Example 3 and Comparative Examples 1-6 Analysis of physical and chemical properties test and efficacy test results: As shown in Tables 1-3, compared with Example 1, the active particles of Comparative Example 1 do not contain a shell layer, and the mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene therein are directly exposed to the suspending agent, the sustained-release mechanism cannot work, the prevention effect decays rapidly, and the active particles have poor dispersibility in the suspending agent, affecting the physical and chemical properties; compared with Example 1, the amount of aminosilicone oil used in Comparative Example 2 is too much, and the shell layer formed on the active particles is too thick, which is not conducive to the release of the active ingredients (avermectin and cyflumetofen), and the prevention effect is difficult to fully exert. In addition, the thick shell layer is not conducive to the dispersion of the active particles in the suspending agent; compared with Example 1, the active particles of Comparative Example 3 do not contain azobenzene, and there is no disturbing effect of azobenzene, and the active ingredients are difficult to disperse. Compared with Example 1, in Comparative Example 4, the amount of azobenzene used in Comparative Example 4 is too much, and the volume expansion it produces is easy to damage its active particles. After the active particles are damaged, the control effect drops sharply. At the same time, after the active particles are damaged, the core components are exposed to the suspending agent, and the dispersion performance deteriorates. Compared with Example 1, in Comparative Example 5, the active ingredient has poor dispersibility due to the lack of a carrier, and the overall control effect is low. Compared with Example 1, in Comparative Example 6, mesoporous silica is used instead of activated carbon. Mesoporous silica provides relatively few effective adsorption sites for nano-attapulgite, which affects the dispersibility of nano-attapulgite in the core of the active particles, thereby affecting the loading of the active ingredient, resulting in its long-term efficacy being inferior to that of Example 1.

[0054] In the description of this specification, the terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, a feature specified as "first" or "second" may explicitly or implicitly include at least one of such features. In the description of the present invention, "plurality" means at least two, for example, two, three, etc., unless otherwise specifically defined.

[0055] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A suspension concentrate containing abamectin and cyflumetofen, characterized in that: The content is calculated by mass percentage as follows: active carrier particles 25%-32%, thickener 0.4%-3%, preservative 0.1%-0.8%, antifreeze 2%-8%; The active carrier particles include a core and a shell, the core including mesoporous activated carbon, nano-attapulgite, abamectin, cyflumetofen and azobenzene, the nano-attapulgite is dispersed in the pores of the mesoporous activated carbon, the abamectin, cyflumetofen and azobenzene are all adsorbed on the nano-attapulgite, and the shell is aminosilicone oil; the mass ratio of the mesoporous activated carbon, the attapulgite, the abamectin, cyflumetofen, the azobenzene and the aminosilicone oil is (0.6-1.5):(0.6-1.8):(0.4-1):(0.6-1.2):(0.1-2):(0.05-0.6).

2. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, wherein The mass ratio of the mesoporous activated carbon, the attapulgite, the abamectin, the cyflumetofen, the azobenzene and the aminosilicone oil is (0.8-1.2):(0.75-1.5):(0.5-0.75):(0.8-1):(0.2-1.5):(0.1-0.45).

3. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, wherein The median particle size D50 of the active carrier particles is 2 μm-15 μm, and the maximum particle size D90 of the active carrier particles is 10 μm-30 μm.

4. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, wherein The mesoporous activated carbon is subjected to an activation treatment, which includes the following steps: soaking the mesoporous activated carbon in a phosphoric acid solution for 5 hours to 12 hours, and then heating it at 400° C. to 500° C. for 1 hour to 3 hours after drying; the mass concentration of the phosphoric acid solution is 30% to 50%.

5. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, wherein The thickener includes at least one of gum arabic, xanthan gum, carboxymethyl cellulose, bentonite and magnesium aluminum silicate.

6. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, characterized in that The preservative includes at least one of sorbic acid, sodium sorbate, benzoic acid, sodium benzoate and benzisothiazolinone.

7. The suspension concentrate containing abamectin and cyflumetofen according to claim 1, characterized in that The antifreeze agent includes at least one of ethylene glycol, propylene glycol, glycerol and urea.

8. A method for preparing a suspension concentrate containing abamectin and cyflumetofen according to any one of claims 1 to 7, characterized in that: The following steps are involved: Mixing the mesoporous activated carbon and the nano-attapulgite and dispersing them in water to obtain a dispersion; adding the abamectin, the cyflumetofen and the azobenzene to the dispersion, performing a first mixing, and spray drying and granulating to obtain first particles; The first particles are mixed with the amino silicone oil for a second time, and then dispersed in water. Finally, the thickener, the preservative and the antifreeze are added and mixed for a third time to obtain the suspension containing abamectin and cyflumetofen.

9. The method for preparing the suspension concentrate containing abamectin and cyflumetofen according to claim 8, wherein: The first mixing is performed under ultrasonic conditions, the ultrasonic power is 300W-500W, and the first mixing time is 30min-2h; and / or the temperature of the spray drying granulation is 80°C-110°C.

10. Use of the suspension concentrate containing abamectin and cyflumetofen as claimed in any one of claims 1 to 7 in pesticides.

Images